Gelonghui, November 17 | According to the Open Source Securities Research Report, Dongcheng Pharmaceutical (002675.SZ)'s three-quarter report results are under short-term pressure, and research and development of innovative nuclear drugs continues to advance. The company is currently developing a diagnostic drug for Alzheimer's disease, 18F-APN-1607 injection, which is currently in phase III clinical trials. The bank expects that if the 18F-APN-1607 injection is successfully listed in the future, it is expected to contribute to the company's performance increase. Considering that the company's research and development of innovative nuclear drugs continues to advance, and there is a lot of potential room for developing diagnostic drugs for Alzheimer's disease, related products are expected to be gradually implemented in the future and maintain the “buy” rating.
研报掘金丨开源证券：维持东诚药业“买入”评级，后续相关产品有望逐步落地
Research Report Nuggets | Open Source Securities: Maintaining Dongcheng Pharmaceutical's “Buy” Rating, Relevant Products Are Expected to Gradually Implement Subsequent Relevant Products
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.